Editor's key points † Annexin 1 (ANXA1) and formylpeptide-receptor-like 1 (FPR2/ALX) are present in both neuronal and glial dorsal root ganglia cells in rats. † ANXA1 is up-regulated in dorsal root ganglia (DRGs) after inflammatory pain in rats. † Intrathecal ANXA1 acts via FPR2/ ALX and exerts anti-nociception at the level of DRGs after inflammation. † This study adds to our understanding of the mechanisms of action of ANXA1 in inflammatory pain.
No studies to date have addressed the antinociceptive role of ANXA1 and FPR2/ALX at the level of dorsal root ganglia (DRGs). This study was undertaken to investigate a potential involvement of ANXA1 to inhibit nociception through FPR2/ALX in the DRGs in a rat model of inflammatory pain.
Methods

Animal model and surgery
Animal experiments conformed to the Animal Care Committee at Huazhong University of Science and Technology and the guidelines for pain research with laboratory animals. 10 Male Sprague -Dawley rats weighing 250 -300 g were housed in individual cages under conditions of a 12 h/12 h light/dark cycle and with food and water available ad libitum. Inflammation was induced by subcutaneously injecting 50 ml of complete Freund's adjuvant (CFA) (Sigma, St Louis, MO, USA) into the dorsal surface of the rat's left hindpaw as described previously. 11 The injection was performed under anaesthesia by means of ether inhalation. For intrathecal (i.t.) catheterization, animals were anaesthetized with 10% chlorohydrate (0.35 g kg 21 i.p.). Adequate anaesthesia was ascertained by no withdrawal response to a paw pinch. Implantation of i.t. cannulas was performed as described previously. 12 A polyethylene-10 catheter was inserted rostrally between L5 and L6 vertebrae to reach the lumbar enlargement of the spinal cord. The animals were allowed a period of 5 days for post-surgical recovery.
Drugs
The Anxa1 2 -26 (Ac-AMVSEFLKQAWFIENEEQEYVQTVK) 13 peptide was prepared by Boster Biological Technology, Ltd (Wuhan, China), by using solid-phase stepwise synthesis. The FPR2/ ALX agonist 5(S)-6(R)-7-trihydroxyheptanoic-acid-methylester (BML-111) and antagonist N-t-Boc-Phe-Leu-Phe-LeuPhe (Boc1) were purchased from Calbiochem (San Diego, CA, USA). Other materials were obtained from Sigma-Aldrich S.r.L (Milan, Italy). Anxa1 2 -26 , BML-111, and Boc1 were injected via the catheter in a volume of 10 ml followed by 10 ml of saline for flushing. When co-administered Boc1 with ANXA1, we applied the first single-drug injection combined with the equivalent vehicle volume of the second drug. Drugs for i.t. administration were freshly dissolved in saline each test day. BML-111 and Boc1 stock solutions were prepared by dissolving the compounds in dimethylsulphoxide (DMSO); aliquots of this solution were used for subsequent dilution in saline (DMSO:saline 1:3, v/v). After baseline behavioural assessments, i.t. injections of either drug or vehicle were performed at 12 and 1 h before CFA injection. We chose these doses based upon our preliminary experiments.
Immunofluorescence and image analysis
Animals were deeply anaesthetized with 10% chlorohydrate 0.35 g kg 21 and transcardially perfused with saline, followed by 4% paraformaldehyde (in 0.01 M PBS, pH 7.4). L4/5 DRGs were removed, post-fixed for 6 h, and treated with 30% sucrose (in 0.1 M PB, pH 7.4) overnight. Cryosections (12 mm) were cut and stored at 2208C. Mounted DRG sections were allowed to thaw at room temperature. Indirect immunofluorescence was used to detect ANXA1, FPR2/ALX, and glial fibrillary acidic protein (GFAP). For analyses of co-localization of ANXA1 with GFAP, FPR2/ALX with GFAP, and ANXA1 with FPR2/ALX, we used dual-labelling immunofluorescence. Donkey or goat serum was used for blocking for 1 h. Next, the antibodies to ANXA1 (rabbit, Santa Cruz Biotechnology, CA, USA, 1:100), FPR2/ALX (mouse, Sigma-Aldrich, St Louis, MO, USA, 1:200), and GFAP (chicken, Abcam, Cambridge, MA, USA, 1:2000) were incubated for 48 h. FITC-and TRITCconjugated second antibodies were then incubated for 1 h. The sections were examined with a laser scanning confocal microscope (LSM 510, Carl Zeiss, Jena, Germany) using an omnichrome air-cooled helium/neon laser tuned to produce beams at 488 and 568 nm. Five randomly selected sections were used. All immunoreactive positive profiles in a section were outlined, creating an artificial overlay. Measuring the average optical density of double-labelled cells was conducted on confocal images randomly taken from two view fields from each section; measuring was performed using NIH Image J software (Bethesda, MD, USA).
Nociceptive behavioural tests
Thermal hyperalgesia was assessed by using a plantar analgesia meter for paw stimulation (Ugo Basile, Italy) as described previously. 14 Mechanical allodynia was inspected by using an electronic von Frey anaesthesiometer (Ugo Basile, Italy) applied to the plantar surface of the hindpaw. The paw withdrawal thermal latency (PWL) and paw withdrawal mechanical threshold (PWT) were recorded five times with a 5 min interval, for both left and right hindpaws, as the time (s) taken from the onset of radiant heat and handheld force (g) transducer stimulation to withdrawal of the hindpaw. A mean value of these five consecutive measurements was taken for each paw.
Western blot analysis
At 0 (before CFA injection), 1, 7, and 14 days after CFA injection and after behavioural experiments (48 h after CFA treatment) with i.t. injection, animals were killed by decapitation and exsanguination. L4/5 DRGs were removed as previously described 15 and immediately homogenized in ice-chilled lysis buffer (50 mM Tris -HCl, pH 7.5) containing 150 mM NaCl, 0.1% Nonidet P40, 0.1% cholic acid, 2 mg ml 21 leupeptin, 1 mg ml 21 pepstatin, 2 mM phenylmethylsulphonyl fluoride, and 2 mM EDTA. The homogenates were centrifuged at 15 000g for 10 min at 48C to yield the total protein extract in the supernatant. The concentration of protein was measured as previously described. 16 Equal amounts of samples (50 mg) were denatured and subjected to sodium dodecyl sulphate-polyacrylamide gel electrophoresis by using 12% running gels and transferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad Laboratories, Hercules, CA, USA). The PVDF membranes were blocked with 5% non-fat dry milk in Tris-buffered saline with Tween 20 (TBST) (50 mM Tris -HCl, pH 7.5, 150 mM NaCl, and 0.05% Tween 20) for 2 h and incubated with the primary antibody, rabbit polyclonal anti-ANXA1 (Santa Cruz Biotechnology, 1: 500) and anti-b-actin (Sigma, 1:10 000) overnight at 48C. Specific reactive bands were detected using a peroxidaseconjugated goat anti-rabbit secondary antibody (1:8000; Jackson ImmunoResearch, Baltimore, MD, USA) for 1 h. The enhanced chemiluminescence method (ECL plus Western blotting detection reagents; Amersham Biosciences, Little Chalfont, UK) was used to reveal the protein bands. The optical density of each band was measured with a computerassisted imaging analysis system (Quantity One, Bio-Rad, Hemel Hempstead, UK) and normalized to optical density of the housekeeping gene b-actin.
Data analysis and statistics
Data are expressed as mean (SD). Pre-CFA baseline measures were analysed by one-way analysis of variance (ANOVA) for radiant heat and von Frey tests. Post-drug time course measures for hyperalgesia and allodynia were analysed by ANOVA with repeated measures followed by the Newman-Keuls post hoc testing. The immunofluorescent results were analysed with Student's t-test. Western blot results were analysed by one-way ANOVA followed by Dunnett's multiple comparisons. P,0.05 was considered statistically significant.
Results
Localization of ANXA1 and FPR2/ALX in L4/5 DRGs ANXA1-positive cells were detected throughout the L4/5 DRGs. We found ANXA1 to be localized in SGCs as indicated by the co-expression with GFAP and in neurones ( Fig. 1A -C) . Similarly, FPR2/ALX was abundantly expressed in SGCs and some of the DRG neurones ( Fig. 1D -F ). Double immunostaining revealed that ANXA1 was co-localized with FPR2/ALX in both neurones and SGCs of the L4/5 DRGs ( Fig. 1G-I ).
CFA injection induces up-regulation of ANXA1 expression in L4/5 DRGs
The unilateral CFA injection increased ANXA1 expression in L4/5 DRGs on both sides, with the most prominent increase being found in the ipsilateral DRG on day 1 post-CFA injection ( Fig. 2A-I Fig. 5A and C) . In the contralateral hindpaw, PWL and PWT were not significantly altered ( Fig. 5B and D (Fig. 5E and F) . On the contralateral side, the changes in ANXA1 expression were similar to those on the ipsilateral side; notwithstanding the smaller responses, they still differed significantly from the vehicle controls ( Fig. 5E and F) . Fig. 6A and C (Fig. 6E and F) .
Discussion
In the present study, (i) subcutaneous injection of CFA into the rat hindpaw resulted in the up-regulation of ANXA1 in L4/5 DRGs. (ii) In the nociception tests, i.t. administration of the ANXA1-derived peptide Anxa1 2 -26 caused an antinociceptive effect, and the FPR2/ALX agonist BML-111 displayed similar effects to Anxa1 2 -26 , whereas FPR2/ALX antagonist, Boc1, blocked the effects. (iii) ANXA1 expression was up-regulated in the L4/5 DRGs when FPR2/ALX was activated by i.t. Anxa1 2 -26 or BML-111 at a medium dose while it was suppressed when FPR2/ALX was inhibited by i.t. Boc1.
So far, little was known about the specific distribution or function of ANXA1 and FPR2/ALX in DRGs. Our results show that ANXA1 is present in both neurones and SGCs in L4/5 DRGs. These data partially concur with Naciff's finding that ANXA1 was distributed in the perinuclear, and the neurolemma of the rat DRG cellular bodies. 17 In our study, ANXA1 was also observed in the SGCs surrounding the DRG neurones. This difference probably due to the disparities in the epitopes recognized by the antibodies and the protocols applied in both studies. Regarding the epitope recognition, post-translational modifications of ANXA1 in the SGCs, such as cross-linking, might mask immunoreactive epitopes. As for the protocols, Naciff chose 4-mm-thick paraffin-embedded brain sections and pH 2.7 buffer solution, whereas we used 12-mm-thick frozen DRG sections and pH 7.4 buffer solution. Evidence suggested that acidity, fixation conditions, and tissue handling may influence ANXA1 epitopes and result in conflicting cellular distribution. 18 To provide indisputable treatment. By inference, the increased expression of ANXA1 in DRG might be the result of synthesis and release from neurones or glia. Our study does not provide direct evidence for whether FPR2/ALX mediates the inhibitory effects of ANXA1 on activated glial cells and the kind of cells involved in the up-regulation of ANXA1. As a next step, we will perform in vitro studies to further explore the contributions of both cell types, by, for example, establishing a system of co-cultured DRG neurones and SGCs. The up-regulation of ANXA1 was also seen in the contralateral DRG after unilateral CFA injection. This finding, consistent with von Banchet and colleagues' 21 report that a unilateral peripheral inflammation can induce protein changes on bilateral DRGs, implies that the contralateral increase in ANXA1 may be secondary. A possible mechanism comprises the signalling molecules produced by neurones or glia that may diffuse into the systemic circulation 22 and then reach the microenvironment of the contralateral DRG in the absence of blood-nerve barrier. 23 We found that i.t. Anxa1 2 -26 alleviated CFA-induced inflammatory nociception, indicating the involvement of ANXA1 in nociceptive modulation, which accord with previous study that Anxa1 2 -26 inhibits the hyperalgesic effects.
24 ANXA1 was shown to be a novel endogenous ligand of FPR 25 and received much attention as a putative endogenous anti-inflammatory agent. 26 Walther and colleagues 27 indicated that Anxa1 2-26 behaved as an FPR agonist and that FPR antagonists were able to inhibit Anxa1 2 -26 -induced effects. 8 In our study, i.t. administration of the FPR2/ALX agonist BML-111 displayed similar effects as did Anxa1 2 -26 , whereas the antagonist Boc1 blocked the effects. These results support Pieretti and colleagues' 4 finding that exogenous ANXA1 inhibit formalin-induced nociception associated with inflammatory processes through a mechanism that involves FPR. Interestingly, Boc1, when administered alone, aggravated CFA-induced nociception and down-regulated ANXA1 expression. The results might be explained by the concept that an 'endogenous ANXA1 tone' in the DRGs contributes to determining the threshold of inflammatory pain. This is in concordance with the similar endogenous tone in the cannabinoid systems. 28 Moreover, ANXA1 null mice display an increased susceptibility to nociceptive pain. 5 Together, these findings indicate a role for an endogenous ANXA1 tone in modulating nociception. Curiously, the high dose of ANXA1 peptide and BML-111 did not increase but mildly decreased ANXA1 expression. We suggest that, as the expression of ANXA1 increases after Anxa1 2 -26 and BML-111 application, the expression of FRP2/ALX might change, too. Studies reported that FPR2/ ALX expression rapidly changes in the presence of high or low agonist concentrations. 29 30 Our next work will investigate the effects of Anxa1 2 -26 and BML-111 on FPR2/ALX expression in DRG. Hopefully, these new experiments will reveal why high dose of Anxa1 2 -26 and BML-111 do not increase ANXA1 expression, despite the fact that, at the same dose, both Anxa1 2 -26 and BML-111 are able to induce anti-nociceptive effects.
In conclusion, both ANXA1 and FPR2/ALX are distributed in neurones and SGCs in rat L4/5 DRGs. The ANXA1 expression was significantly increased after CFA-induced inflammation. I.T. ANXA1-derived peptide not only attenuated the nociception but also up-regulated ANXA1 expression. More importantly, this up-regulation can be mimicked by i.t. administration of the FPR2/ALX agonist and blocked by its antagonist. Taken together, our results indicate that ANXA1 may contribute to modulating CFA-induced inflammatory pain by acting on FPR2/ALX at the DRG level.
